Publication
Article
Oncology & Biotech News
December 2010Volume4 Issue 12
Advisory Panel Discusses Expanded Indication for Avodart
Author(s):
The FDA has released briefing documents noting that the 5-alpha reductase inhibitor increases the risk of high-risk prostate cancer.
Prior to an upcoming advisory panel meeting to discuss whether GlaxoSmithKline’s Avodart (dutasteride) should receive an expanded indication as a chemopreventive for prostate cancer, the FDA has released briefing documents noting that the 5-alpha reductase inhibitor increases the risk of high-risk prostate cancer. Whatever the panel decides might affect a request from Merck to change the label on Proscar (finasteride) to reflect study findings that it reduces the rate of low-risk prostate cancer.
Articles in this issue
Medulloblastoma Subtypes Are Different Diseases
ASH 2010: CPX-351 Improves Response in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia
ASH 2010: Elotuzumab Highly Active in Patients With Advanced Myeloma
ASH 2010: Intensified R-ACVBP More Effective and More Toxic Than R-CHOP in Diffuse Large B-Cell Lymphoma
ASH 2010: Carfilzomib Shrinks Tumors in More Than One-Third of Pretreated Myeloma Patients
ASH 2010: Brentuximab Vedotin Produces High Response Rate in Relapsed or Refractory Hodgkin Lymphoma
ASH 2010: Bosutinib Shows Promise as First-line Treatment of Chronic Myelogenous Leukemia
ASH 2010: Multiple Benefits Observed for Bortezomib in Newly Diagnosed Myeloma Patients
FDA Green-Lights Phase III Trial for Drug-Eluting Microspheres in Liver Cancer
FDA Requests Label Change for Generic Docetaxel
FDA Considers Approval of Fusilev for Colorectal Cancer
Advisory Panel Discusses Expanded Indication for Avodart
FDA Approves Zactima
Effects of UV Radiation Are Cumulative
People in Britain Say Find Aliens, Cure Cancer
Related Videos
Related Content
